Wells Fargo Upgrades Viridian Therapeutics to Overweight, Raises Price Target to $31

Benzinga Newsdesk www.benzinga.com Positive 90.0%

Neg 0% Neu 0% Pos 90%

Wells Fargo analyst Derek Archila upgrades Viridian Therapeutics (NASDAQ:VRDN) from Equal-Weight to Overweight and raises the price target from $20 to $31.